GSK-3 Inhibitors: A Double-Edged Sword? – An Update on Tideglusib

Theodore Lemuel Mathuram; Lisa M. Reece; Kotturathu Mammen Cherian

doi:10.1055/s-0044-100186

Drug Research, Inhaltsverzeichnis

Drug Res (Stuttg) 2018; 68(08): 436-443
DOI: 10.1055/s-0044-100186

Review

GSK-3 Inhibitors: A Double-Edged Sword? – An Update on Tideglusib

Theodore Lemuel Mathuram

¹Department of Stem Cell and Tissue Engineering, Frontier Mediville (A Unit of Frontier Lifeline and Dr. K. M. Cherian Heart Foundation), Affiliated to University of Madras, Chennai, Tamil Nadu, India

,

Lisa M. Reece

²Sealy Center for Vaccine Development, World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA

,

Kotturathu Mammen Cherian

³Department of Cardiothoracic Surgery, Frontier Lifeline Hospital, Chennai, Tamil Nadu, India

› Institutsangaben

Abstract

GSK-3 inhibitors are an emerging tool for clinical interventions in human diseases and represent a niche area in combinational therapy. They possess diverse facets in applications of nervous system disorders, Type 2 diabetes, regenerative medicine and cancer. However, conflicting reports suggest the controversial role of GSK-3 inhibitors in cancers. This review aims to highlight the rise of GSK-3 inhibitors as tools for molecular-targeted research and its shift to a promising drug candidate. The review also focuses on key GSK-3 inhibitors and their roles in cancer and regenerative medicine with special emphasis to tideglusib. In addition, the decisive roles of GSK-3 in various molecular pathways will be concisely reviewed. Finally, this review concludes the emergence of GSK-3 inhibitors as a ‘double-edged sword’ in the treatment against human diseases cautioning researchers about the potential ramifications of off-target pharmacological effects.

Key words

Tideglusib - GSK-3 inhibitors - cancer drugs

Volltext

Referenzen

References
1 Jope RS, Yuskaitis CJ, Beurel E. Glycogen Synthase Kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochemical research 2007; 32: 577-595
2 Patel P, Woodgett JR. Chapter Eight–Glycogen Synthase Kinase 3: A Kinase for All Pathways?. In: Andreas J. ed. Current Topics in Developmental Biology. Academic Press; 2017. p 277-302
3 Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases. Pharmacology & Therapeutics 2015; 148: 114-131
4 Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells. Current Biology. 1996; 6: 1664-1669
5 Hong M, Chen DCR, Klein PS. et al Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3. Journal of Biological Chemistry 1997; 272: 25326-25332
6 Muñoz-Montaño JR, Moreno FJ, Avila J. et al. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Letters. 1997; 411: 183-188
7 Hampel H, Ewers M, Burger K. et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. The Journal of clinical psychiatry 2009; 70: 922-931
8 Macdonald A, Briggs K, Poppe M. et al. A feasibility and tolerability study of lithium in Alzheimer's disease. International Journal of Geriatric Psychiatry. 2008; 23: 704-711
9 Ilouz R, Kaidanovich O, Gurwitz D. et al. Inhibition of glycogen synthase kinase-3β by bivalent zinc ions: Insight into the insulin-mimetic action of zinc. Biochemical and Biophysical Research Communications 2002; 295: 102-106
10 Ryves WJ, Dajani R, Pearl L. et al. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochemical and Biophysical Research Communications 2002; 290: 967-972
11 Kroczka B, Branski P, Palucha A. et al. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull. 2001; 55: 297-300
12 Meijer L, Skaltsounis A-L, Magiatis P. et al. GSK-3-selective inhibitors derived from tyrian purple indirubins. Chemistry & Biology 2003; 10: 1255-1266
13 Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov. 2007; 6: 464-479
14 Sato N, Meijer L, Skaltsounis L. et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004; 10: 55-63
15 Meijer L, Thunnissen AM, White AW. et al. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chemistry & Biology 2000; 7: 51-63
16 Gompel M, Leost M, De Kier Joffe EB. et al. Meridianins, a new family of protein kinase inhibitors isolated from the Ascidian Aplidium meridianum. Bioorganic & Medicinal Chemistry Letters 2004; 14: 1703-1707
17 Coghlan MP, Culbert AA, Cross DAE. et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chemistry & Biology 2000; 7: 793-803
18 Selenica ML, Jensen HS, Larsen AK. et al. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. British Journal of Pharmacology 2007; 152: 959-979
19 Ying Q-L, Wray J, Nichols J. et al. The ground state of embryonic stem cell self-renewal. Nature 2008; 453: 519-523
20 Palm T, Bolognin S, Meiser J. et al. Rapid and robust generation of long-term self-renewing human neural stem cells with the ability to generate mature astroglia. 2015; 5: 16321
21 Gould TD, Einat H, Bhat R. et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. International Journal of Neuropsychopharmacology. 2004; 7: 387-390
22 Meijer L, Leost M, Lozach O. et al. The paullones: A family of pharmacological inhibitors of cyclin-dependent kinases and glycogen synthase kinase 3. In: Pinna LA, Cohen PTW. eds. Inhibitors of Protein Kinases and Protein Phosphates. Berlin, Heidelberg. Berlin Heidelberg: Springer; 2005. p 47-64
23 de Boer AS, Eggan K. A perspective on stem cell modeling of amyotrophic lateral sclerosis. Cell Cycle. 2015; 14: 3679-3688
24 Meijer L, Bisagni E, Legraverend M. Purine derivatives having, in particular, antiproliferative properties, and their biological uses.In Google Patents. 2001
25 Boitano AE, Wang J, Romeo R. et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010; 329: 1345-1348
26 Rosa AO, Egea J, Martínez A. et al. Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: Implication of ERK1/2 and PPARγ receptors. Experimental Neurology. 2008; 212: 93-99
27 Aguilar-Morante D, Morales-Garcia JA, Sanz-SanCristobal M. et al. Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8. PLOS ONE 2010; 5: e13879
28 Martinez A, Alonso M, Castro A. et al. First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of alzheimer's disease. Journal of Medicinal Chemistry 2002; 45: 1292-1299
29 Teodoro del S. Phase IIa clinical trial on Alzheimer's disease with NP12, a GSK3 inhibitor. Alzheimer's & Dementia 2010; 6: S147
30 Tolosa E, Litvan I, Höglinger GU. et al. for the TI A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Movement Disorders. 2014; 29: 470-478
31 Conde S, Pérez DI, Martínez A. et al. Thienyl and Phenyl α-Halomethyl Ketones: New Inhibitors of Glycogen Synthase Kinase (GSK-3β) from a Library of Compound Searching. Journal of Medicinal Chemistry 2003; 46: 4631-4633
32 Hamann M, Alonso D, Martín-Aparicio E. et al. Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structure–Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimer’s Disease. Journal of Natural Products. 2007; 70: 1397-1405
33 McManus EJ, Sakamoto K, Armit LJ. et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. The EMBO Journal 2005; 24: 1571-1583
34 Liu P, Cheng H, Roberts TM. et al. Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer. Nature reviews Drug discovery 2009; 8: 627-644
35 Pap M, Cooper GM. Role of Translation Initiation Factor 2B in Control of Cell Survival by the Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3β Signaling Pathway. Molecular and Cellular Biology. 2002; 22: 578-586
36 Welsh GI, Miller CM, Loughlin AJ. et al. Regulation of eukaryotic initiation factor eIF2B: Glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Letters. 1998; 421: 125-130
37 Tejeda-Muñoz N, Robles-Flores M. Glycogen synthase kinase 3 in Wnt signaling pathway and cancer. IUBMB Life. 2015; 67: 914-922
38 Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 2008; 4: 68-75
39 Magdaleno SM, Curran T. Brain development: Integrins and the Reelin pathway. Current Biology. 2001; 11: R1032-R1035
40 Beffert U, Morfini G, Bock HH. et al. Reelin-mediated Signaling Locally Regulates Protein Kinase B/Akt and Glycogen Synthase Kinase 3β. Journal of Biological Chemistry 2002; 277: 49958-49964
41 Bock HH, May P. Canonical and non-canonical reelin signaling. frontiers in cellular neuroscience 2016; 10: 166
42 Hur E-M, Zhou F-Q. GSK3 signaling in neural development. Nature reviews Neuroscience. 2010; 11: 539-551
43 Briscoe J, Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013; 14: 416-429
44 Jiang J, Hui C-C. Hedgehog signaling in development and cancer. Developmental Cell. 2008; 15: 801-812
45 Lai EC. Notch signaling: control of cell communication and cell fate. Development 2004; 131: 965-973
46 Foltz DR, Santiago MC, Berechid BE. et al. Glycogen Synthase Kinase-3β modulates notch signaling and stability. Current Biology. 2002; 12: 1006-1011
47 Kitisin K, Saha T, Blake T. et al. TGF-β Signaling in Development. Science's STKE 2007; 2007: cm1-cm1
48 Lebrun J-J. The dual role of TGF in human cancer: From tumor suppression to cancer metastasis. ISRN molecular biology 2012; 2012:
49 Guo X, Ramirez A, Waddell DS. et al. Axin and GSK3-β control Smad3 protein stability and modulate TGF-β signaling. Genes & Development 2008; 22: 106-120
50 Beurel E, Kornprobst M, Blivet-Van Eggelpoël M-J. et al. GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Experimental cell research 2004; 300: 354-364
51 Sun A, Shanmugam I, Song J. et al. Lithium suppresses cell proliferation by interrupting E2F–DNA interaction and subsequently reducing S–phase gene expression in prostate cancer. The Prostate 2007; 67: 976-988
52 Korur S, Huber RM, Sivasankaran B. et al. GSK3β regulates differentiation and growth arrest in glioblastoma. PLOS One 2009; 4: e7443
53 Ronchi A, Salaroli R, Rivetti S. et al. Lithium induces mortality in medulloblastoma cell lines. International journal of oncology 2010; 37: 745-752
54 Hilliard TS, Gaisina IN, Muehlbauer AG. et al. Glycogen synthase kinase 3 beta inhibitors induce apoptosis in ovarian cancer cells and inhibit in vivo tumor growth. Anti-cancer drugs 2011; 22: 978-985
55 Novetsky AP, Thompson DM, Zighelboim I. et al. Lithium and inhibition of GSK3β as a potential therapy for serous ovarian cancer. International journal of gynecological cancer: Official journal of the International Gynecological Cancer Society 2013; 23: 361-366
56 Li H, Huang K, Liu X. et al. Lithium chloride suppresses colorectal cancer cell survival and proliferation through ROS/GSK-3β/NF-κB signaling pathway. Oxid Med Cell Longev 2014; 2014 241864 Epub 2014 Jun 5
57 O’Donovan TR, Rajendran S, O’Reilly S. et al. Lithium modulates autophagy in esophageal and colorectal cancer cells and enhances the efficacy of therapeutic agents in vitro and in vivo. PLOS ONE 2015; 10: e0134676
58 Duffy DJ, Krstic A, Schwarzl T. et al. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling. Molecular Cancer Therapeutics. 2014; 13: 454-467
59 Maeng Y-S, Lee R, Lee B. et al. Lithium inhibits tumor lymphangiogenesis and metastasis through the inhibition of TGFBIp expression in cancer cells. 2016; 6: 20739
60 Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S. et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders. The Journal of Neuroscience 2007; 27: 5766-5776
61 Domínguez JM, Fuertes A, Orozco L. et al. Evidence for irreversible inhibition of glycogen synthase kinase-3β by Tideglusib. Journal of Biological Chemistry 2012; 287: 893-904
62 Morales-Garcia JA, Luna-Medina R, Alonso-Gil S. et al. Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. ACS Chemical Neuroscience 2012; 3: 963-971
63 del Ser T, Steinwachs KC, Gertz HJ. et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: A pilot study. Journal of Alzheimer's Disease 2013; 33: 205-215
64 Lovestone S, Boada M, Dubois B. et al. A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis. 2015; 45: 75-88
65 Höglinger GU, Huppertz H-J, Wagenpfeil S. et al. for the TMRII. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Movement Disorders. 2014; 29: 479-487
66 Wang H, Huang S, Yan K. et al. Tideglusib, a chemical inhibitor of GSK3β, attenuates hypoxic-ischemic brain injury in neonatal mice. Biochimica et Biophysica Acta (BBA) - General Subjects 2016; 1860: 2076-2085
67 Baruah J, Wary K. Tideglusib, an allosteric inhibitor of Glycogen Synthase Kinase (GSK)-3β increases Angiogenic activities of Endothelial Cells. The FASEB Journal 2015; 29 (1 Supplement)
68 Armagan G, Keser A, Atalayın Ç. et al. Tideglusib protects neural stem cells against NMDA receptor overactivation. Pharmacological Reports. 2015; 67: 823-831
69 Swinney ZT, Haubrich BA, Xia S. et al. A four-point screening method for assessing molecular mechanism of action (MMOA) identifies tideglusib as a time-dependent inhibitor of trypanosoma brucei GSK3β. PLoS Neglected Tropical Diseases 2016; 10: e0004506
70 Parameswaran R, Ramakrishnan P, Moreton SA. et al. Repression of GSK3 restores NK cell cytotoxicity in AML patients. 2016; 7: 11154
71 Mossine AV, Brooks AF, Jackson IM. et al. Synthesis of diverse 11C-labeled PET radiotracers via direct incorporation of [11C]CO2. Bioconjugate Chemistry. 2016; 27: 1382-1389
72 Zhou A, Lin K, Zhang S. et al. Nuclear GSK3[beta] promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. Nat Cell Biol. 2016; 18: 954-966
73 Mathuram TL, Ravikumar V, Reece LM. et al. Tideglusib induces apoptosis in human neuroblastoma IMR32 cells, provoking sub-G0/G1 accumulation and ROS generation. Environmental Toxicology and Pharmacology. 2016; 46: 194-205
74 Sun A, Li C, Chen R. et al. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. The Prostate 2016; 76: 172-183
75 Neves VCM, Babb R, Chandrasekaran D. et al. Promotion of natural tooth repair by small molecule GSK3 antagonists. 2017; 7: 39654
76 Bharathy N, Svalina MN, Settelmeyer TP. et al. Preclinical testing of the glycogen synthase kinase-3beta inhibitor tideglusib for rhabdomyosarcoma. Oncotarget 2017; 8: 62976-62983
77 Tseng A-S, Engel FB, Keating Mark T. The GSK-3 Inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chemistry & Biology 2006; 13: 957-963
78 Lin C-L, Wang J-Y, Huang Y-T. et al. Wnt/β-catenin signaling modulates survival of high glucose–stressed mesangial cells. Journal of the American Society of Nephrology 2006; 17: 2812-2820
79 Lim JC, Kania KD, Wijesuriya H. et al. Activation of β-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. Journal of Neurochemistry 2008; 106: 1855-1865
80 Cao H, Chu Y, Lv X. et al. GSK3 Inhibitor-BIO Regulates Proliferation of Immortalized Pancreatic Mesenchymal Stem Cells (iPMSCs). PLOS ONE 2012; 7: e31502
81 Soma T, Fujiwara S, Shirakata Y. et al. Hair-inducing ability of human dermal papilla cells cultured under Wnt/β-catenin signalling activation. Experimental Dermatology. 2012; 21: 307-309
82 Kuure S, Popsueva A, Jakobson M. et al. Glycogen Synthase Kinase-3 Inactivation and Stabilization of β-Catenin Induce Nephron Differentiation in Isolated Mouse and Rat Kidney Mesenchymes. Journal of the American Society of Nephrology 2007; 18: 1130-1139
83 Hoffman MD, Takahata M, Benoit DSM. 6-Bromoindirubin-3′-oxime (BIO) induces proliferation of human mesenchymal stem cells (hMSCs). In. 2011 IEEE 37th Annual Northeast Bioengineering Conference (NEBEC); 2011. p. 1-2
84 Shen S, Xu N, Klamer G. et al. Small-molecule inhibitor of glycogen synthase kinase 3β 6-bromoindirubin-3-oxime inhibits hematopoietic regeneration in stem cell recipient mice. Stem Cells and Development 2014; 24: 724-736
85 Liu L, Nam S, Tian Y. et al. 6-Bromoindirubin-3′-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma Cells. Cancer Research. 2011; 71: 3972-3979
86 Song EY, Palladinetti P, Klamer G. et al. Glycogen synthase kinase−3β inhibitors suppress leukemia cell growth. Experimental Hematology. 2010; 38: 908-921.e901
87 Yu A-S, Zhao L. Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3′-oxime upon ovarian cancer cells. Tumor Biology. 2016; 37: 4857-4864
88 Ribas J, Bettayeb K, Ferandin Y. et al. 7-Bromoindirubin-3[prime]-oxime induces caspase-independent cell death. Oncogene 2006; 25: 6304-6318
89 Gray JE, Infante JR, Brail LH. et al. A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Investigational New Drugs. 2015; 33: 1187-1196
90 Atkinson JM, Rank KB, Zeng Y. et al. Activating the Wnt/β-Catenin pathway for the treatment of melanoma – Application of LY2090314, a novel selective inhibitor of glycogen synthase kinase-3. PLOS One 2015; 10: e0125028